ClinicalTrials.gg
Active, not recruitingNCT06498960STRIDEUpdated Jun 25, 2026

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

An interventional study of CereVasc eShunt System and VP Shunt in Normal Pressure Hydrocephalus, sponsored by CereVasc Inc. Active, not recruiting at 32 sites in 3 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by CereVasc Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hydrocephalus, Normal Pressure with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Hydrocephalus, Normal Pressure · United States.

Planned enrollment
3rd of 15
230 · median 30
Started
2024
the only one that year
No phase
10 of 24
2 open now
Registered
23rd of 24
by date
Lead sponsor
2 of 24
CereVasc Inc

Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 23rd registered.

Hydrocephalus, Normal Pressure

78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.

Browse Hydrocephalus, Normal Pressure studies →

Open to participants now

4 of the 24 studies in Hydrocephalus, Normal Pressure with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Hydrocephalus, Normal Pressure studies recruiting now, 12 (75%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hydrocephalus, Normal Pressure with a site in United States, or all of them as a file.
02

Study summary

Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.

Read the detailed description

The STRIDE study is a prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.

03

Conditions studied

  • Normal Pressure Hydrocephalus
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each subject must meet the following criteria:

  1. Patients ≥60 years old on the day of study
  2. Patient or legally authorized representative is able and willing to provide written informed consent
  3. History or evidence of gait impairment with a duration ≥3 months
  4. Clinical presentation consistent with NPH including two or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with all of the following:

    1. Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans' Index >0.3) and the absence of severe hippocampal atrophy,
    2. Pre-procedure spinal tap test or lumbar drain with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%,
    3. CSF opening pressure ≥8 cmH2O,
    4. Baseline cognitive evaluation assessed by (MoCA) test score ≥12
  5. Patient is willing and able to attend all scheduled visits and comply with study procedures.
  6. Confirmation of anatomy suitable for the eShunt procedure, as determined by evaluation of pre-procedure imaging (CT and MRI) and approved by an independent anatomical screening committee.

Exclusion criteria

Exclusion Criteria:

Each subject may not:

  1. Be unable to walk 10 meters (33 feet) with or without an assistive device
  2. Be diagnosed with obstructive hydrocephalus
  3. Have an active systemic infection or infection detected in CSF
  4. Have had prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
  5. Demonstrate or to heparin or radiographic contrast agents against which the subject cannot be adequately pre-medicated, desensitized or where no alternative is available
  6. Have occlusion or stenosis of the internal jugular vein which would prohibit access to the IPS
  7. Present with venous distension in the neck on physical exam
  8. Have medical conditions associated with prolonged elevation of jugular venous pressure, including jugular vein stenosis or stricture, right sided heart failure, cirrhosis of the liver, arteriovenous fistulas in the arm for dialysis purposes, or an arterial venous fistula or malformation in the neck or brain
  9. Have history of bleeding diatheses, coagulopathy or refuse to consent for blood transfusion in cases of emergency
  10. Have had an ischemic stroke or within 180 days of eShunt procedure
  11. Have documented evidence of a deep vein thrombosis superior to the popliteal vein
  12. Have intrinsic blood clotting disorder
  13. Have medical conditions requiring anticoagulation which is unable to be managed to allow for surgical procedure
  14. Have presence of a posterior fossa tumor or mass
  15. Have a \<1 year
  16. Be currently participating in another interventional (drug, device, etc.) research project that may confound the results of this study.
  17. Have established diagnosis of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, or Lewy body dementia
  18. Be diagnosed with schizophrenia or any psychiatric diagnosis (including depression) that may complicate outcome evaluation
  19. Need an intracranial neurosurgical procedure within 180 days of study index procedure
  20. Be unwilling or unable to comply with follow-up requirements
  21. Have mRS of 0, 5, or 6
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    eShunt System

    Endovascular placement of the eShunt Implant

    Device: CereVasc eShunt System

  • Active comparator
    VP Shunt

    Surgical ventriculo-peritoneal shunt procedure

    Device: VP Shunt

Interventions

  • DeviceCereVasc eShunt System

    The eShunt System consists of the following components: * eShunt Implant * eShunt Delivery Catheter and Transfer Tool * eShunt Anchor

    Also known as: eShunt System, eShunt Implant

  • DeviceVP Shunt

    Control arm - VP shunt

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint

    The Primary Effectiveness Endpoint of this study is change in gait impairment at 6-months, compared to baseline. Change in gait impairment is defined as reduction in time required to complete the Timed Up and Go (TUG) test (stand up, walk 3m, turnaround, walk 3m, sit down).

    Time frame: 6 months

  2. Primary Safety Endpoint

    All adverse events will be reported for the investigational (eShunt System) and control (VP shunt) arms. Safety will be analyzed based on a review of all AEs in the investigational arm compared to the control arm, through 6-months post-procedure to demonstrate an acceptable safety profile of the eShunt System.

    Time frame: 6 months

07

Study locations

32 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.

Of 21 interventional studies with no phase under Hydrocephalus, Normal Pressure, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Jul 12, 2024
StartActual
Nov 26, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2031
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06498960
Lead sponsor
CereVasc Inc
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
Nov 26, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jul 2031 (estimated)
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion